This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.

Accept
Creating a Future Immune to

Immunotherapy is the most promising cancer treatment of our time.
With your support, we can fund more breakthrough research
and more cures for cancers of all kinds.
Why Immunotherapy Support the Cause
87 Cents of every dollar spent goes to programs
All Cancers can potentially be treated with immunotherapy
$30.2 Million awarded in 2020
3,400+ scientists supported globally

We are the Cancer Research Institute

Since 1953, we've led the field with support for immunotherapy research and clinical trials. Together with our donor, patient, and scientist communities, we continue to fund revolutionary breakthroughs to cure all types of cancer.

Learn more about our strategy and impact

Why Cancer Immunotherapy?

By harnessing the innate powers of the body's immune system, immunotherapy treatments have the potential to achieve complete, long-lasting remissions and cures for all types of cancer. Immunotherapy is already saving lives, and while responses vary from patient to patient, with further research, we can bring more effective treatments to more cancer patients.

See how immunotherapy works

Funding the Best Scientists

See Where Your Money Goes

All Together for Team CRI

Fundraise for immunotherapy

I'm the Answer to Cancer

Share Stories and Connect

Partners in Progress

Become a corporate sponsor

News & Events

November 24, 2020
Oswald’s Partner in the Fight
In February 2017, Oswald became one of the first patients to receive pembrolizumab...
Read Article
November 17, 2020
Helping Speed a COVID-19 Vaccine
CRI Fellow Susan Klaeger, Ph.D., is optimizing a method to identify which antigens...
Read Article
December 05, 2020
Virtual Immunotherapy Patient Summit Part 2
We are thrilled to offer the first CRI Virtual Immunotherapy Patient Summit. ...
Read More
November 11, 2020
Combination Drug Strategies Gain Ground in PD-1/PD-L1 Pipeline
Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1...
Read Release

*Immunotherapy results may vary from patient to patient.

CRI.ContactUs

Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111

800-992-2623212-832-9376Staff Directory

Stay Connected with CRI

Follow us

Recent Blog Posts

In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.

Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.
Top